- WuXi Biologics was named “Biologics CDMO of the Year” (Large CDMOs) at the 2026 CDMO Leadership Awards, marking its ninth consecutive win.
- The company was also recognized across multiple categories and highlighted its global platform, technology capabilities, and manufacturing performance metrics.
WuXi Biologics has been named “Biologics CDMO of the Year” in the Large CDMOs category at the 2026 CDMO Leadership Awards, marking its ninth consecutive year receiving recognition. The awards, presented by Life Science Connect and hosted by Outsourced Pharma, are based on independent research and sponsor feedback.
In addition to the top award, WuXi Biologics received recognition across several categories, including Best Scaling Support, Best Analytical Services, Best Overall Staff, and Best Project Management within the biologics large CDMO segment. The company stated that these recognitions reflect its continued focus on integrated platforms supporting biologics discovery, development, and contract manufacturing.
As of the end of 2025, WuXi Biologics reported a portfolio of 945 integrated projects, with more than half involving complex modalities such as bi- and multi-specific antibodies and antibody-drug conjugates. The company also reported reduced timelines, including six months from DNA to IND and 15 months from IND to BLA, compared with longer industry averages.
The company highlighted its manufacturing capabilities, including the use of single-use bioreactors ranging from 2,000 L to 5,000 L and configurations enabling up to 16,000 L scale. It also reported a 100% success rate in process performance qualification campaigns and more than 350 large-scale batches delivered since 2017. WuXi Biologics further noted its global quality system, including 46 regulatory inspections passed and 15 GMP-certified facilities.
“We are honored to receive the CDMO Leadership Award for the ninth consecutive year. This recognition reflects the continued trust of our global partners and the dedication of our more than 13,000 employees worldwide.”
Dr. Chris Chen, CEO of WuXi Biologics
